Pharmacogenetics: Global clinical markers

Pharmacogenomics

Volumn 9, Issue 4, 2008, Pages 371-373

  Marsh, Sharon ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; AZATHIOPRINE; CYTOCHROME P450 2D6; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; TAMOXIFEN; THIOPURINE METHYLTRANSFERASE;

BLOOD TOXICITY; BREAST CANCER; DATA BASE; DISEASE MARKER; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG INFORMATION; DRUG MEGADOSE; DRUG SAFETY; EDITORIAL; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HUMAN; LOW DRUG DOSE; NEUTROPENIA; PHARMACOGENETICS; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; GENETIC MARKERS; HUMANS; PHARMACOGENETICS; WORLD HEALTH;

EID: 44949141414     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.4.371     Document Type: Editorial

References (23)

1. Sachidanandam R, Weissman D, Schmidt SC et al.: A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409, 928-933 (2001).
2. Frazer KA, Ballinger DG, Cox DR et al.: A second generation human haplotype map of over 3.1 million SNPs. Nature 449, 851-861 (2007).
3. Marsh S, McLeod HL: Pharmacogenomics: from bedside to clinical practice. Hum. Mol. Genet. 15, R89-R93 (2006).
4. Evans WE, McLeod HL: Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 348, 538-549 (2003).
5. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J. Natl Cancer Inst. 99, 1290-1295 (2007).
6. Innocenti F, Ratain MJ: Irinotecan treatment in cancer patients with UCT1A1 polymorphisms. Oncology 17, 52-55 (2003).
7. Hall D, Ybazeta G, Destro-Bisol G, Petzl-Erler ML, Di Rienzo A: Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenetics 9, 591-599 (1999).
8. Han JY, Lim HS, Shin ES et al.: Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J. Clin. Oncol. 24, 2237-2244 (2006).
9. Engen RM, Marsh S, van Booven DJ, McLeod HL: Ethnic differences in pharmacogenetically relevant genes. Curr. Drug Targets 7, 1641-1648 (2006).
10. Garte S, Gaspari L, Alexandrie AK et al.: Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol. Biomarkers Prev. 10, 1239-1248 (2001).
11. Wild CP, Yin F, Turner PC et al.: Environmental and genetic determinants of aflatoxin-albumin adducts in the Gambia. Int. J. Cancer 86, 1-7 (2000).
12. Dandara C, Sayi J, Masimirembwa CM et al.: Genetic polymorphism of cytochrome P450 1A1 (Cyp1A1) and glutathione transferases (M1, T1 and P1) among Africans. Clin. Chem. Lab. Med. 40, 952-957 (2002).
13. Teixeira RL, Miranda AB, Pacheco AG et al.: Genetic profile of the arylamine N-acetyltransferase 2 coding gene among individuals from two different regions of Brazil. Mutat. Res. 624, 31-40 (2007).
14. Estrela RC, Ribeiro FS, Carvalho RS et al.: Distribution of ABCB1 polymorphisms among Brazilians: impact of population admixture. Pharmacogenomics 9, 267-276 (2008).
15. Jakobsson M, Scholz SW, Scheet P et al.: Genotype, haplotype and copy-number variation in worldwide human populations. Nature 451, 998-1003 (2008).
16. Oliveira E, Quental S, Alves S, Amorim A, Prata MJ: Do the distribution patterns of polymorphisms at the thiopurine S-methyltransferase locus in sub-Saharan populations need revision? Hints from Cabinda and Mozambique. Eur. J. Clin. Pharmacol. 63, 703-706 (2007).
17. Goetz MP, Rae JM, Suman VJ et al.: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23, 9312-9318 (2005).
18. Gaedigk A, Coetsee C: The CYP2D6 gene locus in South African Coloureds: unique allele distributions, novel alleles and gene arrangements. Eur. J. Clin. Pharmacol. (2008).
19. Reynolds S: SPORE study provides new guidelines for tamoxifen use. NCI Cancer Bulletin 3, 1-2 (2006).
20. Sistonen J. Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S: CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet. Genomics 17, 93-101 (2007).
21. Jin Y, Desta Z, Stearns V et al.: CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl Cancer Inst. 97, 30-39 (2005).
22. Schroth W, Antoniadou L, Fritz P et al.: Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol. 25, 5187-5193 (2007).
23. Marsh S, van Booven DJ, McLeod HL: Global pharmacogenetics: giving the genome to the masses. Pharmacogenomics 7, 625-631 (2006).